Last 26 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -2.64 | — | — | — | 0.22 | — | — | — | — | — | 3.85 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 2.69 | — | — | — | 0.14 | 18.30 | — | 9.30 | 1.78 | 31.84 | 91.45 | 80.23 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | -92.2% | -42.5% | — | -88.4% | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 1.20 | 0.14 | 2.35 | 1.79 | 0.25 | 0.43 | 0.20 | — | 290.27 | 15.65 | 7.16 | — | — | 17.48 | 5.54 | 6.45 | 5.08 | 2.84 | 3.32 | 3.69 | 13.89 |
| — | -68.8% | +1085.8% | — | -99.9% | -97.2% | -97.2% | — | — | -10.4% | +29.3% | — | — | +515.6% | +66.6% | +74.8% | -63.4% | -66.2% | -29.6% | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | -0.28 | — | — | — | — | — | 1.42 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | -0.28 | — | — | — | — | — | 1.42 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | — | — | — | 100.0% | 100.0% | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — | — | — | — | — | — |
| — | — | — | — | 0.0% | 0.0% | — | 0.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -122.7% | — | — | — | 40.3% | -11729.7% | — | -3298.4% | -57.4% | -2974.7% | -8619.6% | -5978.1% | — | — | — | — | — | — | — | — | — |
| — | — | — | — | +170.3% | -294.3% | — | +44.8% | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | -102.4% | — | — | — | 61.6% | -13056.8% | — | -2974.6% | -64.1% | -4024.7% | 2341.2% | -6195.9% | — | — | — | — | — | — | — | — | — |
| — | — | — | — | +196.1% | -224.4% | — | +52.0% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -100.2% | -32.8% | -24.0% | -35.2% | 40.5% | -58.4% | -36.5% | — | -291.6% | -321.4% | 45.9% | — | — | -124.8% | -83.9% | -62.9% | -34.1% | -20.5% | -19.7% | -34.1% | -27.3% |
| — | +43.9% | +34.2% | — | +113.9% | +81.8% | -179.5% | — | — | -157.6% | +154.7% | — | — | -508.9% | -326.1% | -84.4% | -24.8% | +25.4% | +16.2% | +40.3% | +41.3% | |
| ROA | -37.7% | -17.3% | -13.9% | -20.4% | 17.7% | -20.3% | -8.4% | -26.2% | -12.7% | -32.7% | 6.7% | -36.4% | -39.6% | -30.5% | -29.4% | -27.8% | -18.7% | -12.7% | -14.3% | -26.0% | -20.3% |
| — | +14.6% | -66.5% | +22.4% | +239.1% | +38.1% | -224.7% | +28.0% | +67.8% | -7.2% | +122.9% | -31.1% | -111.8% | -140.3% | -106.0% | -6.7% | +7.9% | +41.7% | +18.4% | +29.0% | +43.0% | |
| ROIC | -294.3% | -109.3% | — | -82.9% | 51.6% | -117.8% | — | -88.8% | — | -91.6% | — | -118.5% | -79.5% | -379.5% | -572.7% | -915.5% | -2951.7% | -95.0% | -103.9% | -92.4% | -69.8% |
| — | +7.2% | — | +6.7% | — | -28.5% | — | +25.0% | — | +75.9% | — | +87.1% | +97.3% | -299.6% | -451.0% | -890.6% | -4130.8% | +45.1% | +57.5% | +82.9% | -88.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.44 | 0.75 | — | 0.44 | — | 1.81 | — | — | — | 8.37 | — | — | — | 4.14 | — | 1.24 | — | 0.48 | 0.39 | 0.11 | 0.23 |
| — | -58.9% | — | — | — | -78.4% | — | — | — | +102.3% | — | — | — | +758.4% | — | +985.7% | — | +848.2% | +878.6% | +3902.8% | +4728.0% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.85 | 5.06 | — | 5.85 | — | 3.42 | — | 2.01 | — | 2.80 | — | 1.18 | 1.46 | 2.81 | — | 4.51 | — | 6.47 | 7.55 | 8.03 | 4.16 |
| — | +48.2% | — | +191.5% | — | +22.0% | — | +70.2% | — | -0.2% | — | -73.9% | — | -56.6% | — | -43.8% | — | +32.6% | +39.8% | +261.2% | +34.7% | |
| Quick Ratio | 5.85 | 5.06 | — | 5.85 | — | 3.42 | — | 2.01 | — | 2.80 | — | 1.18 | 1.46 | 2.81 | — | 4.51 | — | 6.47 | 7.55 | 8.03 | 4.16 |
| — | +48.2% | — | +191.5% | — | +22.0% | — | +70.2% | — | -0.2% | — | -73.9% | — | -56.6% | — | -43.8% | — | +32.6% | +58.9% | +261.2% | +34.7% | |
| Interest Coverage | -8.83 | -23.89 | -10.58 | -7.38 | 4.20 | -19.85 | -3.46 | -12.33 | -4.28 | -27.43 | 4.97 | -27.32 | -31.26 | -25.73 | -18.74 | -12.05 | -10.06 | -20.98 | -37.22 | -107.66 | -110.27 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 26 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying EVAX stock.
Evaxion Biotech A/S's current P/E is -2.6x. The average P/E over the last 1 quarters is 0.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Evaxion Biotech A/S's current operating margin is -122.7%. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Evaxion Biotech A/S's business trajectory between earnings reports.